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Desmuslin gene knockdown causes altered
expression of phenotype markers and
differentiation of saphenous vein smooth
muscle cells
Ying Xiao, PhD,a Zhibin Huang, MD,b Henghui Yin, PhD,a Hui Zhang, PhD,a and
Shenming Wang, PhD,a Guangzhou, People’s Republic of China
Objective: Phenotypic alterations of vascular smooth muscle cells (VSMCs) appear critical to the development of primary
varicose veins. Previous study indicated desmuslin, an intermediate filament protein, was differentially expressed in smooth
muscle cells (SMCs) isolated from varicose veins; thus, it was naturally hypothesized that altered desmuslin expression might
in turn affect the functioning of VSMCs, leading to the phenotypic alterations and varicose vein development.
Methods: In this study, expression of desmuslin in normal human saphenous vein SMCs was knocked down using small
interfering RNA (siRNA), and control cells were treated with a scrambled siRNA sequence. The levels of several
phenotypic markers including smooth muscle (SM) -actin and smooth muscle myosin heavy chain (SM-MHC) were
assessed. Collagen formation, matrix metalloproteinase expression (MMP-2), and cytoskeletal and morphological
changes were also examined.
Results: SMCs treated with desmuslin siRNA exhibited significantly increased levels of collagen synthesis and MMP-2
expression and decreased expression levels of SM -actin, SM-MHC, and smoothelin and exhibited disassembly of actin
stress fibers when compared with the control cells. Changes in cell morphology and actin fiber networks in VSMCs treated
with desmuslin siRNA were consistent with a lower degree of differentiation.
Conclusions:These results indicated desmuslin expression is required for the maintenance of VSMC phenotype. Decreased
desmuslin expressionmay affect differentiation of VSMCs and ultimately contribute to the development of varicose veins.
( J Vasc Surg 2010;52:684-90.)
Clinical Relevance: Primary varicose veins are a frequent and refractory disease of the peripheral veins. Improved
understanding of the cellular and molecular mechanisms involved may allow the identification of additional targets for
pharmacologic intervention.The development of primary varicose veins is the most
common disease of peripheral veins and affects 10% to 40%
of individuals between the ages of 30 and 70 years.1 The
mechanisms underlying the pathogenesis of this condition
remain unclear.
From the aVascular Surgery Institute, Department of Vascular Surgery, First
Affiliated Hospital of Sun Yat-sen University and the bDepartment of
Cardiology, Memorial Hospital of Sun Yat-sen University.
Supported by the National Natural Science Foundation of China (Grant No.
30471685), the Natural Science Foundation of Guangdong Province
(Grant No. 071173650), and the First Affiliated Hospital of Sun Yat-sen
University and Academy of Life Science (Grant No. 162006).
Competition of interest: none.
Reprint requests: Prof. Shenming Wang, Department of Vascular Surgery,
The First Affiliated Hospital of Sun Yat-sen University, Zhongshan Road,
510080 Guangzhou, People’s Republic of China (e-mail: shenmingwang@
sohu.com).
The editors and reviewers of this article have no relevant financial relationships
to disclose per the JVS policy that requires reviewers to decline review of any
manuscript for which they may have a competition of interest.
0741-5214/$36.00
Crown Copyright © 2010 Published by Elsevier Inc. on behalf of the
Society for Vascular Surgery. All rights reserved.doi:10.1016/j.jvs.2010.03.069
684The principal function of mature vascular smooth mus-
cle cells (VSMCs) is contraction. These cells have a high
cytoplasmic volume fraction of myofilaments,2,3 a low rate
of proliferation,4 and synthesize only small amounts of
matrix proteins.5 VSMCs are not terminally differentiated
cell, and have been shown to undergo phenotypic switch-
ing in association with various abnormal physiological con-
ditions. More importantly, the differentiation of VSMCs
has been implicated in various vascular pathologies, includ-
ing atherosclerosis,6,7 intimal hyperplasia,8,9 and varicose
vein formation.10-14
Several studies have described phenotypic alterations of
VSMCs in varicose veins.10-14 Specifically, it has been re-
ported that VSMCs isolated from varicose veins exhibit
phenotypic transformation from a contractile to a synthetic
state.10-14 Electron microscopic analysis of these cells fur-
ther revealed that they were poorly differentiated, with an
increased presence of secretory cytoplasmic organelles
(suggesting unusual synthetic and secretory roles for these
VSMCs) and a reduction in filament bundles (implying
decreased contractile capability).10
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to the formation of varicose veins.15-17 Indeed, differen-
tially expressed genes in VSMCs isolated from varicose
veins have been identified.18-21 These genes consist of
extracellular matrix (ECM) molecules and cytoskeleton
proteins.
Previous studieshave shownthatmatrixmetalloproteinase-2
(MMP-2) plays a pivotal role in regulating and rearranging
the ECM components of the venous wall.22 Moreover,
findings from recent studies raise the interesting possibility
that increased MMP-2–induced venous relaxation can lead
to progressive venous dilatation, chronic venous insuffi-
ciency, and varicose vein formation.23,24
Intermediate filament (IF) protein, in combination
with microtubules and microfilaments, constitutes the cy-
toskeleton of SMCs. IF proteins consist of a family of
proteins that share common structural and sequence fea-
tures. The IF network has previously been regarded as a
fixed cytostructure that solely provides mechanical integrity
to the cell.25However, it is now known that not only do IFs
form coordinated interactions with other cytoskeletal ele-
ments and organelles, but they also interact with non-
cytoskeletal proteins (eg, chaperones, enzymes, receptors,
etc.) forming networks that can affect diverse cellular func-
tions.26 Furthermore, recent studies demonstrate that the
IF cytoskeleton is a dynamic signaling platform involved in
cell growth, differentiation, and other fundamental biolog-
ical behaviors.27,28
In a previous study, we found that desmuslin, a type VI
IF protein29 and a component of the extensive cytoskeletal
network, was significantly downregulated in SMCs isolated
from varicose veins.18 This led us to hypothesize that
altered desmuslin expression may deleteriously affect the
functioning of venous wall SMCs, leading to phenotypic
alterations and contribute to the development of varicose
veins. To begin to investigate this possibility, we isolated
SMCs from normal human saphenous veins and examined
the expression levels of a number of VSMC phenotype
markers (including smooth muscle [SM] -actin, SM my-
osin heavy chain [SM-MHC], and smoothelin) after des-
muslin gene knockdown using small interfering RNA
(siRNA).30,31 Collagen formation, MMP-2 expression,
and morphological changes were also assessed.
MATERIAL AND METHODS
VSMCs. Smooth muscle cells were isolated from hu-
man saphenous veins. Twelve veins were obtained from
patients undergoing coronary bypass surgery. The patients
were eight men and five women with a mean age of 58.7
1.2 years (range, 52-68 years). Preoperative evaluation of
these patients revealed an absence of varicose abnormali-
ties.
All patients provided informed consent prior to the
procedure and the study was approved by the ethics com-
mittee of the First Affiliated Hospital of Sun Yat-sen Uni-
versity. The investigation conformed with the principles
outlined in the Declaration of Helsinki.Cell culture. Explants from the medial layer of saphe-
nous veins were prepared as previously described.12 To
avoid contaminating the preparation with fibroblasts, we
carefully removed the adventitia and then scraped the lu-
minal surface to remove the endothelial cells. Furthermore,
after cutting the vessel into 2- 2- mm explants, we placed
the explants with the luminal side down in a Petri dish. Cells
were grown in 25-mL flasks in Dulbecco’s modified Eagle
medium (Hyclone; Thermo Scientific, Waltham, Mass)
supplemented with 10% fetal bovine serum (Hyclone), 2
mmol/l L-glutamine, 105 U/L penicillin, 100 g/mL
streptomycin, and 100 g/mL nonessential amino acids.
Incubation conditions were: 37°C, 95% O2, and 5% CO2.
The culture mediumwas changed every 2 days. Cell growth
began within 7 to 14 days, with confluence being attained
after 4 weeks. After attaining confluence, cells were
trypsinized and seeded at densities of 10,000 cells/cm2
(first passage) in uncoated culture flasks. Further subcultur-
ing was performed. Only cells from passages 0 to 2 were
used for experimentation. Before each experiment, the
SMCs were confirmed by immunofluorescence using
a monoclonal antibody against human -actin (clone
ASM-1; Chemicon International Inc, Billerica, Mass).
SMCs from each donor were separately cultured and
studied as outlined in the following sentence. Desmuslin
knockdown studies were performed on cells obtained from
every patient, while phenotype marker assessment and
MMP-2 expression was assessed in cells obtained from
five patients, collagen synthesis in cells obtained from four
patients, and morphology in cells obtained from three
patients.
Transfection of VSMCs with short interfering
RNA. Two 21-nucleotide siRNA sequences targeting hu-
man desmuslin at exons 4 and 1 were synthesized (Ambion
Inc, Austin, Tex) on the basis of mRNA sequences NM-
015286 and NM-145728. A scrambled siRNA sequence
with the same nucleotide composition as desmuslin siRNA,
but lacking significant sequence homology to the human
genome, served as an experimental control. The oligo
siRNA sequences can be seen in the Table. VSMCs were
seeded into 6- or 24-well plates and, upon attainment of
80% to 90% confluence, were transfected with siRNA using
Lipofectamine 2000 (Invitrogen, Carlsbad, Calif) accord-
ing to the manufacturer’s procedure. The subsequent
transfection efficiency was estimated by Western blotting.
Western blotting. Protein extracts were obtained
by disrupting the transfected cells in lysis buffer. Superna-
Table 1. Oligo siRNA sequences used for desmuslin
gene knock-down
Oligo 1: sense 5= 3=GCACACGGUCAAAUGAGAGTT
anti-sense 5= 3=CUCUCAUUUGACCGUGUGCTT
Oligo 2: sense 5= 3=GCCUUACCAUGCAUUUCCGTT
anti-sense 5= 3=CGGAAAUGCAUGGUAAGGCTG
Scramble: sense 5= 3=GUGAGACCGUAAACGCAATT
anti-sense 5= 3=UUGCGUUUACGGUCUCACTTtants containing cytoplasmic proteins were collected and
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ninic acid method (Protein Assay Kit; Keygen Biotec, Nan-
jing, China). For each sample, 50 g of total protein was
subjected to sodium dodecyl sulfate polyacrylamide gel
electrophoresis on a 6% to 12% polyacrylamide gel. Sepa-
rated proteins were electrophoretically transferred onto
polyvinylidene fluoride membranes for immunodetection.
After blocking with 5% non-fat milk in 0.02 M Tris and
0.05% Tween 20, membranes were incubated with the
following primary antibodies diluted in blocking buffer:
anti--SM-actin (clone ASM-1), anti-myosin smooth mus-
cle heavy chain, anti-smoothelin (Chemicon International
Inc.), anti-MMP-2, and anti-desmuslin (Santa Cruz Bio-
technology, Inc). Thereafter, samples were incubated with
horseradish peroxidase-conjugated secondary antibodies.
Detected proteins were visualized by enhanced chemilumi-
nescence system (Amersham, Otelfingen, Switzerland).
Band densities were quantified and normalized with refer-
ence to -tubulin (Sigma-Aldrich, St. Louis, Mo).
Collagen synthesis assay. Culture media containing
50 Gi/ml L-[3,4-3H] proline (China Institute of Atomic
Energy, Beijing, China) was added to each well containing
transfected cells. After 48 hours of incubation, media were
removed from the cells. Trichloroacetic acid (TCA) was
then added to the cells at a concentration of 10% and the
cells left on ice for 1 hour. Following centrifugation at
3000  g for 30 minutes, the precipitated protein was
washed with 4 mL of ice-cold 10% TCA to remove any
unincorporated labeled proline and then re-centrifuged.
The supernatant was carefully removed and the pellet re-
suspended in 0.3 mL of 0.3 MNaOH/0.3% sodium dode-
cyl sulfate. Preparations were then warmed to 37°C until
solubilized, and 4 mL of liquid scintillant was added.
Radioactivity was counted in both the media and cell layer
samples using a liquid scintillation analyzer. The amounts
of radioactivity incorporated into soluble and insoluble
extracellular protein fractions provide an assessment of
collagen released into the media (soluble protein) relative
to that released and then incorporated in and around the
cell layer (insoluble protein).32
Assessment of VSMC by Immunofluorescence sta-
ining. Immunofluorescence staining was performed to de-
tect cytoskeleton changes in transfected VSMCs. Cells (2
103) on coverslips were washed in phosphate-buffered sa-
line (PBS) and fixed in methanol at20°C for 10 minutes.
The cells were then preincubated in 10% bovine serum
albumin for 10 minutes at room temperature to block
nonspecific binding. Following this, the cells were incu-
bated with a monoclonal antibody against human -actin
(clone ASM-1; Chemicon International Inc) diluted in a
solution containing 1  PBS and 0.1% Triton X-100 for
one hour at room temperature with shaking. After washing
with PBS three times (10 minutes each wash), cells were
incubated with the appropriate combination of secondary
antibodies (FITC-conjugated anti-goat IgG [HL] or
rhodamine-conjugated anti-mouse IgG; Jackson Immu-
noresearch, Baltimore, Md) with gentle shaking for 30
minutes. Following three washes with PBS, cells weretreated with DAPI to facilitate detection of nuclei. The cells
were mounted in fluorescent mounting medium (Invitro-
gen) and then examined by immunofluorescence micros-
copy.
The assembly of the actin cytoskeleton into parallel and
elongated stress fibers is a hallmark of differentiated
VSMCs.33 Hence, immunofluorescence-labeled trans-
fected cells were examined under a Zeiss confocal micro-
scope, and images were captured using Zeiss lasersharp
software. All experiments thus described were performed at
least in triplicate.
Statistics. Data are presented as mean  standard
deviation or median (interquartile range). Betweengroup
comparisons were made by one-way analysis of variance.
Post-hoc assessments were made by Bonferroni approach
or Wilcoxon-rank sum test depending on the distribution.
Analyses were performed using SAS 9.0 statistical software
(SAS Institute Inc, Cary, NC). A P value of .05 was
considered statistically significant.
RESULTS
Expression of phenotype markers in siRNA-treated
VSMCs. Two siRNA oligos were tested for knock-down
of desmuslin expression in VSMCs. The two bands (210
KDa and 180 KDa) are the two desmuslin isoforms (Fig 1).
Fig 1. Desmuslin downregulation by short interfering RNA
(siRNA) in vascular smooth muscle cells (VSMCs). VSMCs were
transfected with desmuslin siRNA oligos 1 or 2 or siRNA scramble.
A subset of cells was also mock transfected. Desmuslin protein
levels were assessed byWestern blot and normalized with reference
to -tubulin levels. Representative blots are shown. The results are
presented as mean  standard deviation as determined from three
independent experiments (ie, cells were obtained from three dif-
ferent patients). *P .05 vs scramble; **P .05 vsmock; ***P .05
vs oligo 1.Of these siRNA oligos, transfection with oligo 1 resulted in
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all further experimentation.
The protein expression levels of -SM-actin, SM-MHC,
and smoothelin in VSMCs transfected with desmuslin
siRNA were assessed by Western blot. Significantly lower
protein expression levels of each of these markers were
apparent in siRNA-treated cells compared with control
(siRNA scramble-treated) cells (all P  .05; Fig 2).
Protein expression levels of MMP-2 were significantly
increased in the desmuslin-siRNA-transfected cells com-
pared with control-siRNA-transfected cells (P  .05;
Fig 3).
Collagen synthesis in siRNA-treated VSMCs.
Incorporation of L-[3,4-3H] proline into the cell layer
(insoluble fraction) and in the medium (soluble fraction) of
VSMCs was significantly increased (three- and four-fold)
following inhibition of the desmuslin gene (both P  .05;
Fig 4).
Morphology of siRNA-treated VSMCs. Confocal
microscopic examination of desmuslin siRNA-treated
Fig 2. Expression of vascular smooth muscle cell ph
smooth muscle myosin heavy chain [SM-MHC], and s
interfering RNA (siRNA). Control cells were transfected
blot and normalized with reference to -tubulin levels.
mean standard deviation as determined from five indep
patients). *P  .05 vs scramble.
Fig 3. Expression of matrix metalloproteinase-2 (MMP
knockdown by short interfering RNA (siRNA). Control c
assessed byWestern blot and normalized with reference t
are presented as mean  standard deviation from five
different patients). *P  .05 vs scramble.VSMCs stained for actin revealed disassembly of actin stressfibers (Fig 5). Cells transfected with control siRNA had
parallel and dense actin filaments characteristic of differen-
tiated VSMCs, while cells treated with desmuslin siRNA
had dispersed and thinner filaments. Cells transfected with
control siRNA retained a normal, spindle-like morphology,
while cells transfected with desmuslin siRNA were polygo-
nal in shape. Desmuslin-knockdown cells were also ob-
served to be much larger than control cells.
DISCUSSION
In the present study, we tested the hypothesis that
desmuslin expressionmay affect the functioning of VSMCs,
causing alterations in phenotype. Using siRNA to knock-
down the expression of desmuslin, we found that expres-
sion levels of smooth muscle-specific structural proteins
including SM -actin, SM-MHC, and smoothelin de-
creased significantly, while the synthesis of total collagen
increased remarkably. These previously unreported find-
ings suggest that desmuslin may play a role in controlling
pe-dependent markers (smooth muscle [SM] -actin,
helin) following desmuslin gene knockdown by short
siRNA scramble. Protein levels were assessed byWestern
esentative blots are shown. The results are presented as
nt experiments (ie, cells were obtained from five different
vascular smooth muscle cells following desmuslin gene
ere transfected with siRNA scramble. Protein levels were
bulin levels. Representative blots are shown. The results
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tractile proteins (including SM-MHC) is necessary for op-
timal force development/contraction in SMCs,34,35 and
that increased expression of SM-MHC correlates with a
greater Vmax of contractile shortening in these cells.36
Furthermore, decreased expression of SM -actin has been
shown to correlate with decreased contractility.37 The find-
ings from these studies indicate that proper contraction of
SMCs requires expression of the full complement of con-
tractile proteins, and that alterations in expression contrib-
ute significantly to changes in the contractile properties of
Fig 4. Collagen synthesis in vascular smooth muscle ce
(siRNA) as indicated by incorporation of L-[3,4-3H] pr
transfected with siRNA scramble. The results are present
four independent experiments (ie, cells were obtained fr
Fig 5. Representative immunofluorescence micrographs of vas-
cular smooth muscle cells transfected with scramble small inhibi-
tory RNA (siRNA) and desmuslin siRNA. Cells transfected with
siRNA scramble exhibited parallel and dense actin filaments, while
cells treated with the desmuslin siRNA had dispersed and thinner
filaments. Cells transfected with siRNA scramble retained a normal
spindle-like morphology, while cells transfected with desmuslin
siRNA were more polygonal in shape. Desmuslin-knockdown cells
were larger than control cells.these cells.Contractility is essential for the maintenance of vessel
wall tone in human saphenous vein smooth muscle
cells.38,39 Indeed, impaired contractility of VSMCs has
been previously shown to be associated with the develop-
ment of varicose veins.10 In the present study, we found
that the expression levels of contractile proteins (including
SM-MHC) were significantly decreased in VSMCs trans-
fected with desmuslin siRNA. Although we did not make
any assessments of contractility, these observations suggest
that altered desmuslin expression may result in decreased
contractility of VSMCs. This altered contractility may, in
turn, contribute to the pathogenesis of varicose veins.
We observed that treatment of VSMCs with desmuslin
siRNA resulted in dramatic cell morphological changes.
Specifically, cell shape changed from spindle-like to polyg-
onal, and reorganization of the actin cytoskeleton, an im-
portant mediator of cell contractility, was apparent. This
finding is consistent with that from a report indicating that
IFs play a central role in maintaining cytoarchitecture.27
Indeed, VSMCs treated with desmuslin siRNA in the
present study exhibited an unstructured network of actin
filaments, with the filaments being dispersed and thinner
compared with those in control cells. Coincidentally, we
also found that expression of MMP-2 was significantly
increased in VSMCs transfected with desmuslin siRNA. As
previously noted, MMP-2 plays an important role in regu-
lating and rearranging the ECM components of the venous
wall.22 Hence, increased MMP-2 expression in the present
study may have contributed to the observed alterations in
morphology. Such changes would presumably impact cell
contractility. Further studies are required to assess this
possibility.
Despite compelling evidence showed that phenotypic
modulation of the SMCs plays a key role in varicose vein
development and that desmuslin gene silencing evokes
de-differentiated phenotypic switching, relatively little is
known about how this process is regulated in vivo. One way
to investigate the mechanisms through which inhibition of
r desmuslin gene knockdown by short interfering RNA
into the cell layer (A) and media (B). Control cells were
the median and interquartile range as determined from
ur different patients). *P  .05 vs scramble.lls afte
oline
ed asdesmuslin causes SMCs phenotype is to determine whether
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previously shown to regulate SMCs differentiation. For
instance, it is well documented that RhoA activity is crucial
for regulating SMCs differentiation and the assembly of
actin stress fibers and F-actin.40 Furthermore, evidence is
now emerging that desmuslin influences some cell re-
sponses by modulating the dynamics of actin.41 Thus,
further investigation regarding the physical and functional
interaction between desmuslin and RhoA is warranted to
determine how desmuslin regulates the differentiation of
SMCs.
To our knowledge, little is known about how desmus-
lin maintains the structural integrity of SMCs. A previous
study has shown, however, that desmuslin helps maintain
the integrity of skeletal myofbers by affecting expression of
alpha-dystrobrevin, desmin, and other structural pro-
teins.42 Desmuslin may act in a similar manner in SMCs.
This study has a number of limitations that warrant
mention. As already noted, we did not assess contractility of
the transfected VSMCs. Given the changes reported herein,
we would presume that consequential changes in contrac-
tility would be apparent. Further studies are warranted to
confirm this. Further studies are also needed to elucidate
the precise molecular mechanisms through which desmus-
lin influences expression of the various factors examined in
the present study. Such characterization is yet to be re-
ported. Animal studies (including those involving knock-
out mice) should also be performed to confirm the findings
in an in vivo setting. We did not make any between-gender
comparisons in this study. As varicose vein development
is more common in women, it would be interesting to
compare VSMC desmuslin expression between men and
women. To our knowledge, such a comparison has not
been made to date. A final limitation is the fact that saphe-
nous veins were obtained from patients older than most
patients who develop varicose veins. Desmuslin expression
should be assessed in VSMCs obtained from younger pa-
tients to determine whether there are any age-related
changes.
In summary, this is the first detailed in vitro study to
demonstrate that phenotypical changes can be induced in
VSMCs by altering expression of desmuslin. Our findings
suggest that desmuslin expression is essential for the main-
tenance of the differentiation state of VSMCs. Low or
insufficient expression of desmuslin may affect the differen-
tiation of VSMCs leading to decreased contractility, poten-
tially contributing to the development of varicose veins.
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